Ensysce Biosciences is a clinical-stage pharmaceutical company developing innovative opioid formulations designed to relieve severe pain while reducing the potential for misuse, abuse, and overdose. The company's two proprietary molecular delivery platforms—TAAP (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistant)—use prodrug chemistry and physiological mechanisms to prevent intravenous, intranasal, and oral abuse while protecting against overdose at higher doses. Its lead candidate, PF614, is a modified extended-release oxycodone developed for acute and chronic pain, with a combination product PF614-MPAR undergoing clinical evaluation; the company currently has no approved products or commercial revenue and depends on regulatory approval and commercialization of its candidates to generate future sales, with development supported by federal grant funding.